Attention Deficit Hyperactivity Disorder Market: By Age Group (Children and Adults), By Disorders (Predominantly Inattentive, Predominantly Hyperactive-Impulsive, and Combined), and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Attention Deficit Hyperactivity Disorder Market size was valued at USD 15,836.5 million in 2023 and is poised to grow at a (CAGR) of 5.2% from 2024 to 2030. Attention-deficit hyperactivity disorder (ADHD) is characterized by symptoms of hyperactivity, impulsivity, and inattention, making it a recognized neurological condition. The exact cause of ADHD remains unidentified, though it is believed to result from a complex interplay of genetic predispositions, prenatal brain injuries, environmental factors such as exposure to toxins, and early developmental influences. The expansion of the market can be credited to the increasing demand for drugs used in treating attention deficit hyperactivity disorder (ADHD), spurred by the growing prevalence of ADHD worldwide. This trend is bolstered by heightened awareness of the disorder among healthcare providers and patients, alongside rising healthcare spending in different geographical areas. According to a study published in the Italian Journal of Paediatrics in 2023, the global prevalence of ADHD in children aged 3 to 12 years is 7.6%, while it is 5.6% for those aged 12 to 18 years.

The Forbes Health Report of 2023 indicates that approximately 129 million adolescents and children between 5 to 19 years old are living with ADHD. Nevertheless, stringent regulatory oversight and increasing medication costs, coupled with limited access to non-stimulant ADHD drugs, are expected to pose significant challenges to the growth of the attention-deficit hyperactivity disorder (ADHD) market in the upcoming years. Additionally, concerns about contraindications and side effects associated with ADHD medications are impacting the quality of life for patients, further hindering potential market expansion in the near term.

Attention Deficit Hyperactivity Disorder Market Key Developments:
  • In June 2023, Akili, a renowned digital medicine company, announced the launch of its over-the-counter version of the attention-improving game for adults suffering from attention deficit hyperactivity disorder.
  • In January 2023, Inflow, a United Kingdom-based start-up that focuses on ADHD management through its applications, announced that it had raised US$ 11 million in a series A funding round led by Octopus Ventures along with other investors. The application helps patients manage ADHD through its Cognitive Behavioural Therapy-based support and the company intended to use the raised capital to expand its team and boost product development.

Attention Deficit Hyperactivity Disorder Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

5.2%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Attention Deficit Hyperactivity Disorder Market Dynamics

The COVID-19 pandemic has had a profound impact on the ADHD market, with governments worldwide intensifying efforts to address the disorder in children. A study published in November 2020 in 'Frontiers in Psychiatry' found that ADHD symptoms worsened notably among children during the pandemic. The stress induced by COVID-19 heightened vulnerability among ADHD patients. During the projected period, the global market for ADHD therapeutics is poised for growth due to the increasing prevalence of the disorder. A study published in February 2021 revealed that globally, the prevalence of persistent adult ADHD was 2.58%, with symptomatic cases at 6.76%, impacting approximately 139.84 million and 366.33 million adults, respectively, in 2020. This rise in ADHD cases is expected to drive demand for treatment, thereby boosting the market in the coming years. Moreover, increased focus on research and development is leading to the advancement of effective treatments for ADHD, driving market expansion. For example, a study published in May 2020 in NeuroImage Clinical highlighted a significant trial funded by the Medical Research Council for GBP 1.3 million, involving 100 adolescents with ADHD.

Attention Deficit Hyperactivity Disorder Market Segmentation

By Age Group
  • Children
  • Adults

 

By Disorders
  • Predominantly Inattentive Presentation
  • Predominantly Hyperactive-Impulsive Presentation
  • Combined Presentation

Frequently Asked Questions

In 2023, the global market size for attention deficit hyperactivity disorder (ADHD) was valued at approximately USD 15,836.5 million, with projections indicating a compound annual growth rate (CAGR) of 5.2% from 2024 to 2030.

The global attention deficit hyperactivity disorder market is segmented based on age group, disorders, and geography.

The key players in the attention deficit hyperactivity disorder market are Eli Lilly and Company, Pfizer Inc., Johnson & Johnson Services Inc., Lupin, Novartis AG, Takeda Pharmaceutical Company Limited, Mallinckrodt Inc., Purdue Pharma LP, Supernus Pharmaceutical, Inc., Zevra Therapeutics, Tris Pharma, Otsuka Pharmaceutical, and RespireRx.

The drivers of the ADHD market include increasing awareness and diagnosis of ADHD among both children and adults, advancements in research leading to improved treatment options, and rising investments in healthcare infrastructure and mental health services globally. These factors collectively contribute to the expanding demand for ADHD therapeutics and care solutions.

Stringent regulatory oversight and increasing medication costs, coupled with limited access to non-stimulant ADHD drugs, are expected to pose significant challenges to the growth of the attention-deficit hyperactivity disorder (ADHD) market in the upcoming years. Additionally, concerns about contraindications and side effects associated with ADHD medications are impacting the quality of life for patients, further hindering potential market expansion in the near term.

Key Features of the Reports

  • The attention deficit hyperactivity disorder market report provides granular level information about the Market size, regional Market share, historic Market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key Market developments, and key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the Market.
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the Market.
  • The report provides a plethora of information about Market entry strategies, regulatory framework, and reimbursement scenarios.
1.Executive Summary
2.Global Attention Deficit Hyperactivity Disorder Market Introduction 
2.1.Global Attention Deficit Hyperactivity Disorder Market  - Taxonomy
2.2.Global Attention Deficit Hyperactivity Disorder Market  - Definitions
2.2.1.Age Group
2.2.2.Disorders
2.2.3.Region
3.Global Attention Deficit Hyperactivity Disorder Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Attention Deficit Hyperactivity Disorder Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Attention Deficit Hyperactivity Disorder Market  By Age Group, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Children
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Adults
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
6.Global Attention Deficit Hyperactivity Disorder Market  By Disorders, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Predominantly Inattentive Presentation
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Predominantly Hyperactive-Impulsive Presentation
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Combined Presentation
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
7.Global Attention Deficit Hyperactivity Disorder Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. North America
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Europe
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Asia Pacific (APAC)
7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Middle East and Africa (MEA)
7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
7.5. Latin America
7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.5.3. Market Opportunity Analysis 
8.North America Attention Deficit Hyperactivity Disorder Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. Age Group Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.1.1.Children
8.1.2.Adults
8.2.  Disorders Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.2.1.Predominantly Inattentive Presentation
8.2.2.Predominantly Hyperactive-Impulsive Presentation
8.2.3.Combined Presentation
8.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.3.1.United States of America (USA)
8.3.2.Canada
9.Europe Attention Deficit Hyperactivity Disorder Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Age Group Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Children
9.1.2.Adults
9.2.  Disorders Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Predominantly Inattentive Presentation
9.2.2.Predominantly Hyperactive-Impulsive Presentation
9.2.3.Combined Presentation
9.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Germany
9.3.2.France
9.3.3.Italy
9.3.4.United Kingdom (UK)
9.3.5.Spain
10.Asia Pacific (APAC) Attention Deficit Hyperactivity Disorder Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Age Group Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Children
10.1.2.Adults
10.2.  Disorders Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Predominantly Inattentive Presentation
10.2.2.Predominantly Hyperactive-Impulsive Presentation
10.2.3.Combined Presentation
10.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.China
10.3.2.India
10.3.3.Australia and New Zealand (ANZ)
10.3.4.Japan
10.3.5.Rest of APAC
11.Middle East and Africa (MEA) Attention Deficit Hyperactivity Disorder Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Age Group Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Children
11.1.2.Adults
11.2.  Disorders Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Predominantly Inattentive Presentation
11.2.2.Predominantly Hyperactive-Impulsive Presentation
11.2.3.Combined Presentation
11.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.GCC Countries
11.3.2.South Africa
11.3.3.Rest of MEA
12.Latin America Attention Deficit Hyperactivity Disorder Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Age Group Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Children
12.1.2.Adults
12.2.  Disorders Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Predominantly Inattentive Presentation
12.2.2.Predominantly Hyperactive-Impulsive Presentation
12.2.3.Combined Presentation
12.3.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Brazil
12.3.2.Mexico
12.3.3.Rest of LA
13. Competition Landscape
13.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
13.2.1.Eli Lilly and Company
13.2.2.Pfizer Inc.
13.2.3.Johnson & Johnson Services Inc.
13.2.4.Lupin
13.2.5.Novartis AG
13.2.6.Takeda Pharmaceutical Company Limited
13.2.7.Mallinckrodt Inc.
13.2.8.Purdue Pharma LP
13.2.9.Supernus Pharmaceutical, Inc.
13.2.10.Zevra Therapeutics
13.2.11.Tris Pharma
13.2.12.Otsuka Pharmaceutical
13.2.13.RespireRx
14. Research Methodology 
15. Appendix and Abbreviations 
  • Eli Lilly and Company
  • Pfizer Inc.
  • Johnson & Johnson Services Inc.
  • Lupin
  • Novartis AG
  • Takeda Pharmaceutical Company Limited
  • Mallinckrodt Inc.
  • Purdue Pharma LP
  • Supernus Pharmaceutical, Inc.
  • Zevra Therapeutics
  • Tris Pharma
  • Otsuka Pharmaceutical
  • RespireRx

Adjacent Markets